BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:Faculty Seminar Elisa Oricchio: Integrating multiple dimensions to
  understand tumor evolution and design new therapies
DTSTART:20250404T121500
DTEND:20250404T131500
DTSTAMP:20260315T154813Z
UID:488171765f5ed542df6a92a2408e325cfb129d4d5393e806aa1626e0
CATEGORIES:Conferences - Seminars
DESCRIPTION:Prof Elisa Oricchio\nAbstract:\nCancer is a disease that adapt
 s and evolves in response to various growth conditions and environmental s
 ignals through genetic\, epigenetic\, and transcriptional modifications. T
 he genetic evolution of a tumor occurs as a result of the gradual accumula
 tion of various genomic alterations\, such as mutations and chromosomal ab
 normalities. However\, tumors can continue to progress and develop resista
 nce to treatments even without acquiring new genetic changes\, underscorin
 g the importance of non-genetic mechanisms in tumor evolution. In my labor
 atory\, we are interested in understanding the interplay between genetic a
 nd epigenetic mechanisms and how they influence tumor initiation and respo
 nse to anti-cancer therapies. In particular\, over the past years\, we hav
 e determined how cancer cells co-opt the tridimensional (3D) structure of 
 the chromatin in the nucleus to support tumor development and progression.
  Moreover\, we have demonstrated how the acquisition of specific genomic a
 lterations changes the interaction between cancer cells and the tumor micr
 oenvironment. By integrating these different layers of tumor biology\, we 
 have designed and developed new anti-cancer therapies.\n\nBio:\nElisa Oric
 chio is an Associate Professor at EPFL and currently serving as director o
 f the Swiss Institute for Experimental Cancer Research (ISREC@EPFL) and co
 -director of the Swiss Cancer Center Leman. She received her Ph.D. in 2008
  and did her post-doctoral training at Memorial Sloan Kettering Cancer Cen
 ter\, where she gained expertise in cancer genomics\, genetic manipulation
  of transgenic animal models\, and pre-clinical treatment studies. Current
 ly\, her research focuses on cancer genomics\, 3D chromatin organization\,
  and B-cell malignancies. Throughout her career\, she has identified on
 cogenes or tumor suppressor genes as new therapeutic targets or as biomark
 ers to better classify cancer patients. She has integrated linear cancer g
 enomic analyses with tridimensional analyses of the genome to better under
 stand tumor development and evolution. The translational impact of her wor
 k has been recognized with the 2024 EACR-Pezcoller Foundation Translation
  Research Award\, the Prix Leenaards for Translation Research\, and other 
 awards. She is a board member and representative of young scientists of t
 he European Association of Cancer Research (EACR)\, which is the major as
 sociation for cancer research in Europe.\n\nThis seminar is part of the ev
 aluation of Prof. Oricchio for the promotion to Full Professor.\n 
LOCATION:SV 1717 https://plan.epfl.ch/?room==SV%201717 https://epfl.zoom.u
 s/j/61944586526
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR